Shree Ganesh Biotech India Ltd

Despite a broadly positive market environment, Shree Ganesh Biotech India Ltd has reached a fresh all-time low of Rs 0.51 on 19 Aug 2026, underscoring persistent pressures on the stock that have outpaced sectoral and benchmark indices.

Shree Ganesh Biotech India Ltd’s stock price reached a new 52-week low of Rs.0.51 on 12 August 2026, marking a significant decline over the past year amid persistent financial pressures and subdued market performance.

For the sixth consecutive session, Shree Ganesh Biotech India Ltd closed lower, touching a fresh all-time low of Rs 0.52 on 12 Aug 2026. This marks a continuation of a steep decline that has seen the stock lose 35.0% over the past year, significantly underperforming the Sensex's modest 3.25% fall during the same period.

Shree Ganesh Biotech India Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹22.00 crores, continues to struggle with operational profitability as the company posted operating losses in Q1 FY27. Trading at ₹0.55 per share as of August 4, 2026, the stock has witnessed a precipitous decline of 30.38% over the past year, substantially underperforming the Sensex which declined 3.20% during the same period. With zero promoter holding, minimal institutional interest at 1.42%, and a concerning "Strong Sell" rating with a score of just 12 out of 100, the company faces mounting challenges in an already competitive pharmaceutical sector.

The stock of Shree Ganesh Biotech India Ltd has reached a fresh all-time low of Rs.0.52 on 30 Jul 2026, extending a multi-year decline that has seen the share price lose over 90% of its value in the past five years. Despite some recent upticks in profitability, the share price continues to reflect significant investor caution.

Despite a broadly positive market environment, Shree Ganesh Biotech India Ltd has continued its downward trajectory, hitting a fresh all-time low of ₹0.55 on 20 Jul 2026. This marks a significant milestone in the stock’s prolonged decline, underscoring persistent challenges that have yet to be fully addressed.

Despite a broadly positive market environment, Shree Ganesh Biotech India Ltd has continued its downward trajectory, hitting a fresh all-time low of ₹0.56 on 30 Jun 2026. The stock’s persistent underperformance contrasts sharply with sector gains and broader indices, underscoring a complex interplay of valuation pressures and financial challenges.

A sharp decline in the share price has dragged Shree Ganesh Biotech India Ltd to a fresh 52-week low of Rs 0.52 on 11 Jun 2026, marking a 34.83% drop over the past year and signalling sustained pressure on this micro-cap pharmaceutical stock.

Shree Ganesh Biotech India Ltd’s stock price declined to an all-time low of ₹0.58 on 11 June 2026, marking a significant milestone in its ongoing downward trajectory. The company’s shares have underperformed considerably against the broader market and its sector peers, reflecting persistent financial and valuation pressures.

Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Aug 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 15 May 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Shree Ganesh Biotech India Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹24.32 crores, reported a net loss of ₹0.15 crores in Q4 FY26 (Mar'26), marking a sharp deterioration from the ₹0.32 crores profit posted in the previous quarter. The stock, currently trading at ₹0.61, has declined 34.41% over the past year, significantly underperforming the broader market and reflecting mounting investor concerns over the company's operational viability.

Shree Ganesh Biotech India Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Aug 2024. However, the analysis and financial metrics discussed here reflect the company’s current position as of 17 April 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

The micro-cap pharmaceutical company Shree Ganesh Biotech India Ltd has plunged to a fresh all-time low of Rs.0.54 on 1 Apr 2026, extending a multi-year decline that has seen its share price lose over 90% in the past five years. Despite a modest rebound in recent sessions, the stock remains deeply undervalued and faces significant headwinds across valuation and financial metrics.